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INTRODUCTION
Diabetes is a Greek word which means ‘to pass through
‘urine’. It is a syndrome characterized by disturbed
metabolism of carbohydrate, protein, and fat as a result
of  absolute insulin deficiency (Type 1 diabetes mellitus)
or relative insulin deficiency and resistance (Type 2
diabetes). It is the most common endocrine/metabolic
disorder of childhood and adolescence. Diabetes can
occur in all ages in children.
Classification of Diabetes
DM is a heterogeneous entity which was first classified
by the American Diabetes Association in 1979 on the
basis of aetiopathogenesis into four groups, mainly
Type1, Type 2, Other types and Gestational diabetes.
Table 1 is classification modified from ‘Report of  the
Expert Committee on the Diagnosis and Classification
of Diabetes Mellitus’ in 2000 reflecting all major
categories in childhood, including the emergence of
type 2 diabetes mellitus (T2DM) and other causes of
type 1 diabetes mellitus (T1DM).1-2
Type 1 Diabetes Mellitus (T1DM) refers to childhood
diabetes usually associated with autoimmunity and
absolute insulin deficiency, although insulin deficiency
may not be absolute at clinical onset of the disease.3
T1DM is further subclassified into Type 1A associated
with the presence of  islet cell autoantibodies, and Type
1B characterized by the absence of  the antibodies.2-3
Type 2 Diabetes Mellitus (T2DM) is childhood diabetes
associated with obesity and insulin resistance. Maturity-
onset diabetes of  youth (MODY), an autosomal
dorminant DM, is a “milder” form of  diabetes caused
by specific gene defects that impair insulin secretion.4
The more severe forms of  MODY may require insulin
subsequently. Neonatal diabetes is uncommon and
usually transient. Permanent neonatal DM has been
described, which is usually familial and
nonautoimmune.5
This review, which focuses mainly on T1DM, provides
an overview of  the major advances in the
understanding of  the aetiology, pathogenesis and
clinical management of DM in children.
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Diabetes mellitus (DM) is a syndrome characterized by disturbed
metabolism of carbohydrate, protein, and fat. It is a chronic
metabolic disorder caused by an absolute or relative deficiency of
insulin. It presents with very different medical and psychosocial
issues in children.
Epidemiological studies indicate that there is gradual but steady
increase in the incidence of both type 1 diabetes (T1DM) and type
2 diabetes (T2DM) in both developed and developing countries.
The manifestations, therapy goals, clinical course, susceptibility to
complications of diabetes differ among childhood cases.
T1DM accounts for the majority of cases of diabetes in children.
Diabetic ketoacidosis may be the initial presentation of T1DM in
many children particularly in Africa probably due to low level of
awareness.
The focus of  this review on T1DM is to provide an overview of  the
major advances in the aetiology, pathogenesis, and clinical
management of newly diagnosed children and their subsequent
management with the aim of ensuring optimal growth and
development as well as preventing acute and chronic complications.
The advances in insulin therapy and regimens and the presentation
and management of diabetic ketoacidosis are discussed. The
prospects for the cure of the disease are also highlighted in this
review.
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I. Type 1 diabetes (beta cell destruction ultimately leading to complete insulin deficiency)
A.  Immune mediated
B. Idiopathic
II. Type 2 diabetes (variable combinations of  insulin resistance and insulin deficiency)
A. Typical
B. Atypical
III. Genetic defects of ß cell function
A. MODY syndromes
1. MODY 1 Chromosome 20, HNF-4á
2. MODY 2 Chromosome 7, glucokinase
3. MODY 3 Chromosome 12, HNF - 1 á
4. MODY 4 Chromosome 13, IPF – 1
5. MODY 5 Chromosome 17, HNF - 1ß, TCF – 2
6. MODY 6 Chromosome 2q32, Neuro-D1/Beta-2
B. Mitochondrial DNA mutations (includes one form of  Wolfram syndrome; Pearson syndrome; Kearns-
Sayre, diabetes mellitus deafness)
C. Wolfram syndrome – DIDMOAD (diabetes insipidus, diabetes mellitus, optic atrophy, deafness): WFSI-
Wolfram- chromosome.
1. Wolfram locus 2- chromosome
2. Wolfram mitochondrial
D. Thiamine responsive
IV. Drug or chemical induced
A. Antirejection – cyclosporine
B. Glucocorticoids (with impaired insulin secretion, e.g., cystic fibrosis)
C. L- Asparaginase







V.  Diseases of exocrine pancreas








VII. Variants of  type 2 diabetes
A. Genetic defects of insulin action
1. Rabson-Mendenhall syndrome
2. Leprechaunism
3. Lipoatrophic diabetes syndrome
4. Type A insulin resistance-acanthosis
B. Acquired defects of insulin action




2. Anti-insulin receptor antibodies
VIII. Genetic syndromes with diabetes and insulin resistance/insulin deficiency.
A. Prader-Willi syndrome, chromosome 15









A. Transient-cyclic adenosine monophosphate maturation, chromosome
B. Permanent-agenesis of pancreas
- glucokinase deficiency, homozygous
Table 1: Etiologic Classification of Diabetes Mellitus2Epidemiology
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Internationally, there is variation in the incidence and
prevalence of T1DM by race, age, season and
geographic location. The explanation for these
variations is still unclear. Many countries report that
incidence rates have doubled in the last 20 years.6 The
rates are highest in Scandinavia especially Sardinia and
Finland with annual incidence of 34.4 cases/ 100,000
and 40 cases/ 100,000 respectively.7 In the US, incidence
is 15 cases per 100,000 annually and 13.5/100,000 in
the United Kingdom.8 Incidence figures are lowest in
Asia and Africa. In China, annual incidence is 1/100,000
and 7.8/100,000 in Libya.8 In Nigeria, there is a relatively
high prevalence rate of 0.33/1000 among school
children despite potential deaths caused by minimal
medical attention.9 This is probably due to long-term
protein malnutrition and endemic childhood infections,
which have been implicated in the aetiology of  IDDM
in similar populations.
The onset of T1DM has a bimodal pattern with peak
incidence at the age of 6-8 years and during puberty
but onset in the first year of life is unusual.10 There is
no sex predominance.
The onset of T1DM is seasonal with peak in fall and
winter months. This has been suggested as evidence
for viral aetiology, but it may also be due to seasonal
pattern of  higher blood glucose in normal persons
during winter.11
Pathogenesis
The precise aetiology of  T1DM is unknown but some
contributory factors have been identified.
Role of autoimmune process
T1DM occurs as a result of environmental factors
interacting with a genetically susceptible person. The
interaction leads to autoimmune disease directed at
the insulin-producing  cells of the pancreatic islets of
Langerhans and  cell destruction occurs.12  B-cell and
T-cell autoimmune markers are usually present before
the onset of  disease suggesting that the autoimmune
damage is often insiduous.13 B-cell marker, Islet cell
antibody (ICA) is found in 90% of newly diagnosed
patients and can be present 20 yrs earlier in at risk
groups.14 Insulin antibodies (IA) occur at disease onset
in younger patients while glutamic acid decarboxylase
(GAD) antibodies occur in 60-90% of  new cases.14
Insulin deficiency occurs with 90% destruction of 
cells which eventually leads to absolute insulinopenia.
Genetic Role
T1DM is not inherited. It is a multifactorial disease
with a strong genetic component that is thought to
interact with specific environmental triggers. The role
of  genetic factors in the aetiology is supported by the
30 to 50% concordance rate in monozygotic twins.15
Several genetic determinants of  T1DM have been
established. The HLA class II DQ locus on
chromosome 6 is the most important, encoding highly
polymorphic antigen-presenting proteins that account
for almost 50% of  the genetic risk for T1D.14-15 More
recently, high-density genome-wide association studies
have been performed to search for the remaining
T1DM loci.16 In all, 18 loci have been identified to
date as being robustly associated with the pathogenesis
of the disease.16-17
Role of environmental factors
There is 50% to 70% discordance rate of T1DM in
identical twins, suggesting that environmental factors
may trigger the disease in genetically susceptible
individuals.18 Implicated trigger factors are viruses such
as enteroviruses, rubella, coxsackie B, cytomegalovirus,
mumps which are postulated to directly initiate damage
to  cells.19 Exposure to certain chemical toxins and
drugs that specifically destroy pancreatic cells, such as,
rodenticide vacor and streptozotocin, lead to
disruption of  insulin production.20 Furthermore,
breastfeeding seems to provide protection against the
risk of developing T1DM, possibly by direct effect
and delayed introduction of  cow’s milk. It has been
proposed that bovine serum albumin, a protein in cow’s
milk with properties similar to islet cell antigen,
stimulates autoantibody production leading to
destruction of  islet cells.21
Pathophysiology
Progressive destruction of  cells leads to progressive
insulin deficiency. In normal metabolic state, there are
regular swings between the postprandial high insulin
anabolic state and fasted low-insulin catabolic state that
affect three major tissues: liver, muscle and fat as shown
in table 2 below.2
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T1DM as it evolves becomes a permanent low-insulin
catabolic state in which feeding exaggerates the
catabolic state.2 The failure to secrete insulin results in
an inability to oxidize glucose in muscle and adipose
tissue. There is increase in counter regulatory hormones
such as cortisol, adrenaline, glucagon and growth
hormone which lead to further rise in blood glucose
and accelerate the rate of metabolic decompensation.22
The resulting hyperglycaemia leads to osmotic diuresis,
glycosuria and thirst when the renal threshold for
glucose is exceeded. The osmotic diuresis results in
polyuria and secondary polydipsia. Untreated patients
excrete high glucose load causing polyphagia 2
Dehydration occurs when fluid losses exceed intake.
Furthermore, insulin deficiency leads to lipolysis with
production of excess free fatty acids and ketone bodies
leading to ketonuria and metabolic acidosis resulting
in compensatory deep rapid breathing (kussmaul
respiration).23 Coma may occur due to ketosis, acidosis,
dehydration and hyperosmolality.23
Clinical Presentation
The classical presenting symptoms of T1DM are
polyuria, polyphagia, polydipsia, weight loss and
lethargy.24 Onset may be acute, precipitated by an acute
illness, or more chronic and insidious over weeks or
even months.24 Hyperglycemia impairs immunity and
renders a child more susceptible to recurrent infections,
particularly of the urinary tract, skin, and respiratory
tract. Candidiasis may occur, especially in groin and
flexural areas.2 Other features are constipation, anorexia
and blurred vision but the younger children, less than
5 years of age are usually asymptomatic except for
nocturnal enuresis.22 There is therefore need for high
index of suspicion in this age group to prevent late
diagnosis and its consequences such as diabetic
ketoacidosis (DKA). In the developing countries, most
children present for the first time in DKA partly
because of lack of recognition of their symptoms by
health workers.
Diagnosis of Diabetes Mellitus
There was a recent revision of the criteria for the
diagnosis of DM by the American Diabetes
Association’s (ADA) with the definition of  a new
threshold for the diagnosis of impaired glucose
tolerance (IGT) and impaired fasting glucose (IFG).
The criteria for diagnosis of DM include the presence
of at least of one of the following:25
 (i) Symptoms of hyperglycaemia including polyuria,
polydipsia, weight loss plus random plasma glucose
concentration >200 mg/dl (11mmol/L).
(ii) Fasting (> 8 hours) plasma glucose > 126 mg/dl
(7 mmolL).
(iii) 2 hour postprandial glucose >200 mg/dl during
an oral glucose tolerance test (OGTT).
Criteria for diagnosing IGT and IFG are 2 hour plasma
glucose between 140-200 mg/dl (8-11 mmol/L) or a
fasting glucose between 100-125 mg/dl (6-7mmol/
L) respectively.25-26
Early Clinical Course
The natural history of T1DM is in 4 phases of  cell
functional capability.27, 29
 Insulin deficiency at clinical presentation.
 Remission – partial/complete:  Within a few
weeks of  starting insulin therapy, approximately
two thirds of children enter a remission
(‘honeymoon’) period during which endogenous
insulin production increases. Remission can last
weeks to months.27
 Relapse - There is irreversible loss of insulin
secretory capacity in patients with remission with
abrupt increase in insulin requirement. This can
occur gradually or abruptly as a result of
intercurrent infections.27,29
 Total diabetes occurs when there is complete
insulin deficiency as a result of lack of endogenous
insulin secretion. Glycaemic control with
subcutaneous insulin becomes more difficult and
glycemic excursions more profound.27
Investigations
At initial diagnosis of T1DM, it is important to carry
out investigations such as:
1. Blood glucose: Diagnosis is confirmed when there































& Fatty acid release
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Table 2: Glucose homeostasis–Comparison of Fed and
Fasting States
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greater than 200 mg/dl, confirmed on a subsequent
day, or fasting blood glucose greater than 126 mg/dl
on two occasions.28
A formal oral glucose tolerance test is rarely necessary
for diagnosis of T1DM. It can exclude the diagnosis
of diabetes when hyperglycemia or glycosuria occur
as a result of intercurrent illness, steroid therapy or
when the patient’s condition includes renal glucosuria.2,
28 Stress hyperglycemia (a transient increase in blood
glucose during acute stress) may be differentiated from
new onset diabetes by its short duration (1-5 hours)
and without insulin treatment, glucose levels return to
normal.
2. Urine glucose: Glycosuria is suggestive of  DM and
not diagnostic.22
3. Urine ketones: Ketonuria is a marker of insulin
deficiency and potential DKA. Its presence generally
confirms that diabetes is T1DM.22
4. Islet cell antibodies, IA and GAD may be present at
diagnosis but are not needed to diagnose T1DM.2
Management of Type 1 Diabetes Mellitus
Managing children and adolescents with DM is
complex and requires multidisciplinary team including
a paediatrician with expertise in diabetes, diabetes nurse
specialist, dietitian, psychologist, health educator and
social worker.24, 30 The goals of  treating a child with
DM are to achieve (i) normal growth and
development, (ii) prevent acute complications such as
severe hypoglycaemia which when recurrent, is
associated with risk of developing learning disabilities
and neurologic deficits in children less than 5years and
(iii) prevent chronic complications by achieving near
normal blood glucose.24 Duration of  hyperglycaemia
is the most important risk factor for chronic
complications of T1DM. The management of DM
can be divided into long term management and
management of acute complications primarily diabetic
ketoacidosis (DKA).
Long Term Management
At initial diagnosis, hospitalization may not always be
required except in children with the following
conditions: (i) diabetic ketoacidosis, (ii) age less than 5
years, (iii) parents with difficulty understanding the
management program and/or serious psychosocial
problems, (iv) children with psychomotor delay, (v)
families who live outside the region.30
The basic components of  long term management of
T1DM are education and emotional support, diet and
insulin therapy.
Education
Education is a continuous process at every stage of
the life of  the child and the family. It should involve
all members of the diabetes team. Education should
be formal sessions in a clinic or hospital ward setting
and opportunistic teaching at clinics or at home in
response to crises or difficulties such as acute illness.29
A teaching program should be set up for the child
and the family to understand the basic pathophysiology
of diabetes and the importance of adequate metabolic
control to avoid acute and chronic complications. They
should be provided with the skills necessary for
managing children safely at home, basic skills for
survival including insulin administration, blood glucose
monitoring, recognition and treatment of
hypoglycemia, hyperglycemia, and ketoaacidosis,
adjusting insulin and diet for growth, exercise, and sick
days.28-29 They should be encouraged to establish
appropriate behaviours for maintenance of glycaemic
control in early childhood which facilitates compliance
during puberty. They should not be overwhelmed with
information initially and printed educational material
should be used to facilitate long term mastery.28-29
Dietary Management
This is an essential component of diabetes care. A
paediatric dietician should provide education,
monitoring, and support to the child, parents and
extended family.31 The dietician should advise on
planning, content, and timing of snacks/meals in the
context of  each child’s individual circumstances,
lifestyle, and the insulin action profiles. The dietary
recommendations should be based on healthy eating
recommendations appropriate for all children and
adults and the whole family should be encouraged to
make appropriate changes.29,31-32 Basic universal
recommendations are that carbohydrates should
provide 50-60% of  daily energy intake and no more
than 10% should be from sucrose or other refined
carbohydrates. Fat should provide less than 30% and
protein should provide 10-20% of daily intake.29,33 The
aim is to balance the child’s food intake with insulin
dose and activity and to keep blood glucose
concentrations as close as possible to reference ranges
of 80-180mg/dl.31 The diet plan should be developed
for each child to suit individual needs and circumstances
and reviewed regularly.
Insulin Therapy
Insulin is required for treating all forms of  diabetes. It
was isolated in 1921-22 at the University of  Toronto
by Banting, Macleod, Best and Collip. There are 3
species of  insulin - Porcine, Bovine and Human insulin.
Their onset of action, efficacy and side effects are
similar, but human insulin is recommended for children
with diabetes.
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Advances in Insulin Therapy
The most recent advance in insulin therapy was the
development of insulin analogues with the overall aim
that administered insulin would mimic the physiological
release of insulin during the post-prandial and post-
absorptive periods.34-35
Table 3 shows currently available insulin analogues, their
onset and duration of action.
Ultra-short acting insulin analogues are very rapid-acting
(RA) and exist as monomers, thus absorbed in minutes.
They are injected immediately before food and allow
for greater flexibility of meal time. This leads to
improvement in glycaemic control with fewer episodes
of hypoglycaemia.34-35 Examples of ultra-long-acting
insulin analogues are Ultralente, Glargine. They lead to
consistent and prolonged insulin release with no peaks
and constant basal insulin concentration. This leads to
better glycaemic control, less nocturnal hypoglycaemia
and good safety data.35-36
Many non-invasive routes for insulin administration
have been investigated including nasal, buccal, oral,
gastrointestinal, and transdermal. There has been
maximum progress with the inhaled route.37 It is an
insulin analogues with the aim of delivering insulin in
more convenient manner than the traditional
subcutaneous route, thus it may be especially useful
for patients with needle phobia.38 It has been shown
that when inhaled insulin is taken before meals in
addition to a basal insulin injection, it leads to good
glycaemic control similar to that of patients given
multiple dose injections (MDI).39 However, the long
term safety and efficacy of  inhaled insulin is yet to be
established.24
Insulin Delivery Devices
Insulin can be delivered with syringe and needle.
Semiautomatic pen injector devices, disposable
(prefilled) or reusable are now available and generally
preferred by children as they are quicker and easier to
use than syringes and needles.28 Insulin can also be
administered with insulin pumps. They are
programmable pumps containing insulin connected by
infusion line to a small plastic cannula inserted
subcutaneously.28
Insulin Regimens
The aim of insulin therapy is to mimic the physiological
secretion of insulin. At diagnosis, as a rule of thumb
most pre-pubertal children will require 0.5 to 1 unit/
kg/day of insulin. Adolescents may require up to 2
units/kg/day.28 This requirement may be reduced
substantially in the first few months of therapy during
the honeymoon period.28 There are various regimens.
When choosing a regimen, we should bear in mind
the needs and wishes of the family and make changes,
if there are difficulties or poor glycaemic control.
1. Traditional regimen – this is the use of  twice daily
injection using a mixture of ultra-short-acting (RA)
or short-acting (SA) and intermediate-acting (IA)
insulin.  About one third is given as RA/SA and
two-third as IA formulation. About 60-70% of
total daily dose is given before breakfast and 30-
40% is given before supper.2
2. The Basal/bolus regimen – Basal bolus regimen
can be given by multiple daily injection (MDI) or
continuous subcutaneous insulin infusion (CSII)
which uses only rapidly acting insulin. MDI is the
use of RA/SA prior to each main meal with an
injection of LA prior to bedtime. It suppresses
glucose production between meals and overnight.
Usually 30% to 40% of total daily dose of insulin
is given at bedtime as LA and 60% to 70% is
given as RA/SA and split between the three meals.
It allows greater variation in meal times and size
of  meals.36,40
3. Continuous Subcutaneous Insulin Infusion (CSII)
– the use of  insulin pump therapy. It is used in
about 25% of children in the USA and about 1-2
% in the United Kingdom.   They may be used as
Table 3: Onset and Duration of  Action of  Insulin Analogues
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part of an intensive management regimen to
improve glycaemic control. The devices consist
of a programmable pump containing insulin
connected by an infusion line to a small
subcutaneous cannula. One injection site is used
for 2-4 days, hence there is less variation in
absorption due to site rotation and insulin delivery
allows closest match to physiological requirements.
The pump delivers RA/SA insulin continuously
at a basal rate with additional boluses delivered at
meal time. Pump therapy is said to provide the
best and most consistent glycaemic control. It
should be used only by a trained and experienced
team.28,40
Problems of Insulin therapy
• Somogyi phenomenon – This is the rebound
morning hyperglycaemia which may occur
following nocturnal hypoglycaemia caused by
release of  counter regulatory hormones (GH,
glucagon, cortisol & adrenaline).22
• Dawn phenomenon - This is hyperglycaemia
as a result of hypoinsulinaemia which occurs
between 5-9am.  It occurs mainly in puberty
and is thought to be due to insulin resistance
caused by nocturnal GH secretion.22
Blood glucose monitoring
The level of  long term glycaemic control determines
significantly the risk of developing chronic
microvascular complications of diabetes, therefore, it
is important to maintain blood sugars as near normal
as possible and prevent the risk of hypoglycaemia.
Therefore, regular home blood glucose monitoring
should be carried out for the success of intensive
management of  diabetes.24 Generally, a blood glucose
level of 100-200mg/dl (6-12 mmol/L) for preschool
children, 72-180mg/dl (4 -10 mmol/L) for older
children and 72-144mg/dl (4 -8 mmol/L) for
adolescents should be the aim.24
Routine follow up
Children and their parents should be seen regularly in
a designated clinic for follow up by the diabetes team
every 3 to 4 months and assessed for the following:28,30
• general health, including height, weight, blood
pressure, hospital admissions;
• Review of blood glucose monitoring, insulin regimen
and details of hypoglycaemic episodes




• accuracy of the glucose monitor compared with
laboratory blood glucose testing equipment;
• meal plan requirements and adherence;
• knowledge of diabetes, insulin, and diet;
• insulin injections  and examination of injection sites
• attitudes to and management of diabetes,
psychosocial problems and school progress
Children should also be screened for conditions
associated with diabetes and for long-term
complications.
Patients who have had diabetes for 2 years or more
should have annual review with physical examination
for microvascular & other complications of DM
including fundoscopy as detailed in table 4.
They should also have the following investigations:28,30
1. Glycated hemoglobin (HBA1c) - best method for
medium- to long-term diabetic control monitoring.
Levels should be checked every 3 months. Most
clinicians aim for HbA1c values of 7-9%.
2. Thyroid function tests - Untreated thyroid disease
may interfere with diabetes management so thyroid
function should be checked annually if thyroid
antibodies are present.
3. Screening for coeliac disease by measurement of
celiac antibodies annually.
4. Screening for microalbuminuria - From age 12 years,
annual urinalysis needed to test for a increased
albumin excretion rate (AER), referred to as
microalbuminuria, which is an indicator of risk for
diabetic nephropathy
5. Lipid profiles - Children should also be screened
intermittently for lipid abnormalities (fasting serum
lipid profile 6 months after diagnosis and again
during adolescence or when diabetic control is poor.
6. Renal function tests: If  the child is otherwise healthy,
tests typically are not required.













Poor or excessive weight gain
Delayed puberty/menarche
Lipohypertrophy; necrobiosis lipoidica
Dental caries or signs of poor oral
hygiene
Retinopathy/cataracts
Signs of poor foot care e.g. calluses
Limited joint movement
Hypertension
Goitre, signs of hypo- or
hyperthyroidism
Hyperpigmentation of Addison’s disease
Impaired vibration and pinprick sense;
loss of ankle reflex
Source – Reference 28
Table 4: Points to note on examination of patients
with DM at annual review
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Complications of Type1 Diabetes Mellitus
There are 3 major categories:
 Acute complications - reflect the difficulties
of maintaining a balance between insulin
therapy, dietary intake, and exercise.
 Long-term complications - Chronic
complications of diabetes in childhood and
adolescent result from poor glycaemic
control. Complications include short stature
with delayed maturation, limited joint mobility
commonly affecting the interphalangeal joints
and adolescent microvasculopathy, neuropathy
and microalbuminuria.
 complications caused by associated
autoimmune diseases
Acute Complications
These include: DKA, hypoglycemia, and
hyperglycemia. The commonest acute complication of
T1DM is DKA and will be discussed in detail.
Diabetic Ketoacidosis (DKA)
Diabetic Ketoacidosis creates a life-threatening medical
emergency. Therefore, early recognition and careful
management are essential if death and disability are to
be avoided. DKA may be the initial presentation of
T1DM and is the most important cause of mortality
and severe morbidity in children with diabetes,
particularly at the time of  first diagnosis.22 In Africa, it
is the most frequent cause of death in patients with
T1DM. It may occur as a result of an intercurrent
illness or recur if insulin is omitted (recurrent DKA in
adolescence is almost always due to insulin omission).23
The clinical features of DKA are severe dehydration,
shock, frequent vomiting, polyuria despite dehydration,
weight loss in spite of good intake, acetone breath –
(Kussmaul respiration) deep and rapid, altered
sensorium and signs of raised intracranial pressure such
as bradycardia, hypertension and anisocoria.22-23
Diagnosis can be made on clinical and biochemical
grounds. The biochemical criteria for the diagnosis of
DKA include hyperglycemia (glucose >200mg/dl/
11mmol/l), metabolic acidosis (bicarbonate <
15mmol/) and venous PH <7.30 with ketonuria (serum
ketones >5mmol/l).28
Management of DKA
DKA is a medical emergency and like all emergencies,
resuscitation should follow the ‘ABC’ pattern. The
protocol described is largely based on that published
by the European Society for Paediatric Endocrinology
and the Lawson Wilkins Paediatric Endocrine Society41
and by the British Society for Paediatric Endocrinology
and Diabetes.42
Resuscitation
• Admit to the intensive care unit or high
dependency unit if pH<7.00, age < 2 years,
unconscious and blood glucose >1000mg/
dL
• Resuscitation in ABC pattern
• If in shock, oxygen by face mask should be
given.
• If signs of shock (i.e hypotension, severe
peripheral shut-down, oliguria) are present,
resuscitate with boluses of 10 ml/kg of 0.9%
saline, or 0.9% saline plus 5% albumin.  Repeat
as necessary, and then place on maintenance
+ deficit.
Replace fluid requirement over 48 hours. If
the corrected serum sodium value is in the
hypernatraemic range, even slower rehydration
may be considered.
Initial Monitoring
 Hourly pulse rate, respiratory rate, blood pressure,
neurological observations.
 Hourly blood glucose measurement while on an
insulin infusion.
 Accurate fluid balance (an indwelling catheter may
be required).
 2-4 hourly temperature
 Test all urine for ketones until negative.
 Strict fluid balance is essential.  Reassess fluid status
every few hours.  Continuing polyuria may worsen
the dehydration if a positive fluid balance is not
being achieved.  The patient initially should be “Nil
by Mouth.
 Insert a sampling cannula and obtain blood
samples for:
 Baseline blood glucose, electrolytes, calcium,
phosphorus, venous pH and acid base status
(arterial if signs of shock are present), full blood
count, urea and creatinine, triglycerides and sepsis
work up if indicated.
  urine test for ketones and microscopy, culture and
sensitivity.
 Do 2-4 hourly electrolytes and venous pH,
depending on severity and progress.
Electrolyte Replacement
 Sodium replacement is individualised on the basis
of  biochemical monitoring.  The measured serum
sodium concentration is lowered by the dilutional
effect of the coexistent hyperglycaemia and
coexistent hyperlipidaemia. An approximate
corrected sodium can be calculated as follows:
Corrected sodium = Sodium + 1.6(glucose – 5.5)
      5.5
                                             (all values in mmol/l)
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 If corrected sodium is greater than150 mmol/L,
correction of the dehydration and electrolyte
imbalance over 48-72 hours is advocated to
minimize the risk of cerebral oedema.
 Potassium replacement should be started as soon
as resuscitation is completed and prior to
commencing the insulin infusion.  If renal failure
is suspected, withhold potassium until electrolytes
are available and an indwelling catheter is inserted.
 Commence potassium chloride at 5 mmol/kg/
day   Check serum potassium 2 hours later and
then 4 hourly.
 Bicarbonate therapy is generally not required.It
may be considered after consultation in the severely
shocked patient with severe acidosis (i.e. arterial
pH <7.0 and/or HCO3 <5mmo1/L). Cardiac
monitoring is required; hypokalaemia and
exacerbation of  hypernatraemia are risks.
Bicarbonate should be given by an intravenous
infusion over 30 minutes.
Insulin Infusion
 Start after resuscitation is completed and
rehydration and potassium replacement is under
way.
 Add 50 units of short-acting insulin to 500 ml of
0.9% Saline, so that 10 ml of solution will contain
1 unit of insulin.  If an infusion pump is not
available, a soluset may be used.
 The insulin infusion must be clearly labeled so that
confusion with the rehydrating solution does not
occur.
 Start the insulin infusion at 0.05-0.1 units/kg/hr.
It is not necessary to give a priming bolus of
insulin.
 The aim is to produce a fall in blood glucose of
72-90mg/dl (4-5 mmol/L) per hour.  Over the
first two hours, however, rehydration alone will
result in a fall in blood glucose and a larger fall
can be accepted at this time without a reduction
in insulin infusion rate.
 If plasma glucose concentrations fall by more than
90mg/dL/hour add dextrose (5-10%) to the
intravenous fluids.
 When the blood glucose has fallen to 14-17 mmol/
L (250-300mg/dL), intravenous fluid with
dextrose should be prescribed (usually a 5%
dextrose/0.45% saline mixture is used, but
dextrose concentrations of up to 10% may be
necessary to maintain plasma glucose
concentrations).
 The insulin infusion rate and/or the Dextrose
infusion rate should then be adjusted to keep the
blood glucose level between 140 – 220 mg/dl
(8-12 mmol/L).
 The insulin infusion should not be stopped before
the acidosis is corrected as insulin is required to
switch off ketone production.  If the blood
glucose falls <4mmol/L., (<72mg/dL) a bolus
of 2ml/kg of 10% dextrose should be given and
the dextrose concentration in the fluid increased.
 When the pH is >7.30, the blood glucose
concentration has been reduced to 14-17 mmol/
L (250-300mg/dL), and a dextrose infusion has
been started, the insulin infusion rate can be reduced
– but not to less than 0.05 units/kg/hour.
 If the patient still requires IV fluids after 24
hours, use 0.45% saline in 5% Dextrose.
Subsequent Management
 Although plasma glucose concentrations may fall
to near normal levels within 4-6 hours of
treatment of DKA, the metabolic acidosis may
take 24 hours or longer to resolve.
 Blood gases and electrolyte and urea
concentrations should be re-evaluated 2 hours after
the start of treatment and 4-hours thereafter, or
more frequently if there are clinical concerns, until
the child has recovered.
 The ongoing intravenous fluid prescription should
be reviewed every 4 hours and adjusted according
to the electrolyte results and fluid balance.
 If there is continuing massive polyuria, the rate of
infusion of intravenous fluids may need to be
increased and large gastric aspirates will need
replacing with 0.45% saline with 10mmol/L
potassium chloride
 Once the blood gases and electrolyte
concentrations normalize, the frequency of  blood
sampling can be decreased and discontinued once
the child is tolerating oral fluids and food.
 The frequency of bedside capillary blood glucose
measurements may be reduced to 2-to-4-hourly
if plasma glucose concentrations are relatively
stable while the child is receiving intravenous
dextrose.
 If the acidosis or hyperglycaemia do not improve
after 4-6 hours the patient should be reassessed
by a senior doctor.  Insulin errors, inadequate
rehydration or sepsis may be the cause.  More
insulin, 0.9% saline or antibiotics may be required.
 Intravenous fluids should be continued until the
child is drinking well and able to tolerate snacks.
 The insulin infusion should be continued until
significant ketonuria (+++) is no longer present.
However, it is not necessary to wait for complete
resolution of ketonuria before changing to
subcutaneous insulin.
 When the patient is started on a conventional
subcutaneous insulin regimen, the insulin infusion
should be discontinued 30 minutes (if using a short
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and long-acting insulin) after the first subcutaneous
injection to avoid rebound hyperglycaemia.
Cerebral Oedema
This can be a sudden and unpredictable complication
of the therapy of DKA which occurs in the first 24
hours of treatment. It is commoner in children younger
than 10 years (especially < 5 years).2 The aetiology is
poorly understood because it could occur even with
optimum management of DKA.28 It is associated with
25% mortality and neurological sequelae in survivors.28
All patients should therefore be monitored for signs
and symptoms of raised intracranial pressure.  Risk
factors and warning signs include severe dehydration
and shock, severe acidosis and low serum potassium
indicating severe total body loss of potassium,
hypernatraemia indicating a hyperosmolar state,
hyponatraemia, and deteriorating conscious state during
therapy.43,44
If suspected it requires treatment immediately with
mannitol 1-2 g/kg by intravenous infusion over 20
minutes. The rate of  fluid administration should be
reduced. Transfer to an intensive care facility and
arrange a neurological assessment and CT scan.43,44
Prospects for the Cure of Type 1 Diabetes
The mainstay of treatment for T1DM is currently
lifelong insulin therapy. However, cure of  the disease
is being sought through various treatment protocols
including those aimed at replacing ß cells via pancreatic
organ transplantation or islet cell transplantation. These
are:
 Efforts at prevention and early diagnosis through
genetic and immunologic screening of high-risk
children.
 Development of  new and improved insulins.
 Administration of insulin by alternate routes like
nasal, inhalation.
 Improvement in the management and outcome
of pancreatic and islet cell transplantation.28
Pancreatic and islet cell transplantation
 Pancreatic transplantation was first reported in 1966
with significant improvement in operative techniques
and immnosuppressive drugs over the years. 45
Pancreatic transplantation is not generally
recommended in children because of the risks of
surgery and prolonged immunosuppression. 46
Successful islet cell transplantation was first reported
in 1980 and recent advances in immunosuppressive
therapy and transplant biology  with the development
of the regimen called Edmonton protocol led to very
good result of 80% rate of insulin independence and
euglycaemia at 1 year post-transplant. However, longer
term follow up has tempered enthusiasm for this
strategy.47
Techniques are now underway to develop stem cell
therapy to isolate and propagate islet cell progenitor
cells from adult pancreas or extrapancreatic sources
suitable for transplantation.48
In conclusion, T1DM is not uncommon in African
children despite the paucity of data on the
epidemiology in Africa. It is an autoimmune disorder
that is usually triggered by some environmental factors
in genetically susceptible individuals. DKA may be the
initial presentation of T1DM and is the most important
cause of mortality and severe morbidity in children
with diabetes, particularly at the time of  first diagnosis.
In Africa, it is the most frequent cause of death in
patients with T1DM. The risk of complications relates
to diabetic control. With good management, patients
can expect to lead full, normal, and healthy lives.
Mortality and morbidity associated with T1DM
diabetes has perceptually declined with the identification
and widespread use of newer insulins and automated
methods of  delivery via programmable pumps.
Furthermore, there are prospects in islet cell
transplantation and the development of stem cell
therapy for future cure of the disease.
Sadly, this remarkable achievement has not reached
the children who develop diabetes in sub-Saharan
Africa where the onset of childhood diabetes may be
the equivalent of  a death sentence. Two major issues
of importance related to T1DM in developing
countries are missed diagnosis and unavailability of
insulin.
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